Welcome to our dedicated page for Insight Molecular Diagnostics news (Ticker: IMDX), a resource for investors and traders seeking the latest updates and insights on Insight Molecular Diagnostics stock.
Insight Molecular Diagnostics Inc. (Nasdaq: IMDX), or iMDx, generates news primarily around its work in transplant-focused molecular diagnostics. The company’s updates center on its dd-cfDNA-based GraftAssure assay family, regulatory and reimbursement milestones, clinical data, and collaborations with transplant centers and research partners.
News releases frequently describe progress toward clinical and regulatory goals for the GraftAssureDx in vitro diagnostic kit, including clinical trial activity, software validation, and planned submissions to the U.S. Food and Drug Administration and other regulatory authorities. iMDx also reports on coverage decisions and reimbursement developments for its GraftAssureCore laboratory-developed test, which is performed at the company’s CLIA-certified lab in Nashville.
Investors and clinicians following IMDX news can expect coverage of scientific publications and case studies that use the GraftAssure technology to monitor kidney transplant patients, including complex scenarios involving novel therapies. The company highlights registry initiatives designed to generate real-world dd-cfDNA data, as well as conference presentations where iMDx and its collaborators discuss in-house dd-cfDNA testing and transplant rejection monitoring.
Additional IMDX news items include corporate developments such as executive appointments, participation in healthcare and investor conferences, and strategic updates related to the company’s transplant rejection testing strategy. For readers interested in the diagnostics and research sector, the IMDX news feed offers ongoing insight into how dd-cfDNA assays are being developed, validated, and positioned for use in kidney transplant management.
Insight Molecular Diagnostics (Nasdaq: IMDX) submitted GraftAssureDx for FDA de novo review on March 25, 2026 and expects a ~150-day review timeline aiming for authorization in 2026. The company closed a $26 million financing in February, received TÜV SÜD ISO 13485 certification Feb 26, and expects U.K. CE marking via self-certification in Q2 2026.
Clinical updates include a second favorable peer-reviewed, multi-center (249 biopsy-matched patients) study and growing engagement with 37 U.S. transplant centers representing >25% of U.S. transplants; Medicare reimbursement for send-out testing is $2,753 per result.
Insight Molecular Diagnostics (Nasdaq: IMDX) will report Q4 2025 financial results after market close on March 26, 2026, and will host a live Zoom webinar at 2:00 pm PT / 5:00 pm ET the same day with a Q&A session.
An archived replay will be available in the Investors/Events & Presentations section of the company website. Management will also attend the 25th Annual Needham Virtual Healthcare Conference and present in a virtual fireside chat on April 15, 2026.
Insight Molecular Diagnostics (Nasdaq: IMDX) highlighted a peer-reviewed study of 249 biopsy-matched kidney transplant patients showing its GraftAssure Combination Model (CM) score outperformed percentage-only and absolute dd-cfDNA measures in correlating with four histopathology-derived rejection indices.
The company cites a prior World Transplant Congress readout showing a rise in positive predictive value to over 80% at 25% prevalence, and plans to commercialize an IVD kit in 2026 to address a roughly $2 billion transplant testing market.
Insight Molecular Diagnostics (Nasdaq: IMDX) completed key milestones in February 2026 advancing GraftAssureDx toward an FDA De Novo IVD submission. Milestones include a three-site reproducibility study, collection of sufficient clinical samples based on a projected 25–30% rejection rate, and ISO 13485 certification (Feb. 26).
Internal analytical work is nearly complete: about 11,660 of 12,000 instrument and assay cycles finished (roughly 340 remain). Certification enables planned U.K. and EU submissions and supports commercial manufacturing readiness in 2026.
Insight Molecular Diagnostics (Nasdaq: IMDX) announced a registered direct offering of 4,525,976 shares (or pre-funded warrants) at $5.75 per share, expected to close on February 12, 2026, for approximately $26.0 million gross proceeds before fees. Lake Street Capital Markets is sole placement agent.
The company said it will use net proceeds for general corporate purposes, including research and development to expand its GraftAssure transplant diagnostic offering beyond kidney into other organs, most immediately heart transplant testing. Bio-Rad participated on the same terms.
Insight Molecular Diagnostics (Nasdaq: IMDX) praised a Jan. 13, 2026 STAR working group position paper in the American Journal of Transplantation that calls for decentralized, high-quality dd-cfDNA testing. The company says the paper's endorsement of absolute quantification and onsite testing aligns with iMDx's GraftAssure family of assays and supports demand for its kitted diagnostics. iMDx noted GraftAssureCore is an LDT reimbursed by CMS, GraftAssureDx is an IVD kit in development, and management cited a roughly $1 billion-plus addressable market for kitted transplant rejection testing.
Insight Molecular Diagnostics (Nasdaq: IMDX) announced management will attend investor conferences during JPM Week and BTIG Snowbird in winter 2026. Key events: LifeSci Advisors 15th Annual Corporate Access Event (one-on-one meetings, Jan 12, The Beacon Grand, San Francisco), additional JPM Week investor meetings (one-on-one, Jan 12–14, San Francisco), and BTIG 13th Annual Snowbird (one-on-one meetings and skiing, Feb 9–11, Cliff Lodge, Snowbird, Utah). The company provided contact instructions for scheduling in-person meetings via LifeSci Partners or BTIG sales representatives.
Insight Molecular Diagnostics (Nasdaq: IMDX) appointed Dr. Nick Ioannou as Vice President, Medical Affairs effective Jan 6, 2026. Dr. Ioannou brings more than three decades of clinical and medical-affairs experience across organ transplant, nephrology, cardiology, genetics, and oncology.
The hire positions iMDx to support its upcoming commercial transplant rejection assay launch, leveraging his field-based KOL relationships and prior roles at Guardant Health, Natera, CSL Behring, Fresenius, and Baxter.
Insight Molecular Diagnostics (Nasdaq: IMDX) provided a year-end update on its GraftAssure transplant diagnostics program and regulatory progress on GraftAssureDx. The company said ~95% of its planned FDA IVD de novo submission work was complete at year-end 2025, with final software quality-control items remaining and full submission expected in the coming weeks.
Other highlights: 20 global transplant centers engaged by year-end 2025, 17 U.S. centers committed to a registry (≈10% U.S. transplant volume), TÜV SÜD ISO 13485 stage 1 & 2 audits completed, and an accelerated EU/CE/IVDR submission targeted for H1 2026.
Insight Molecular Diagnostics (Nasdaq: IMDX) reported Q3 2025 results and progress toward a planned FDA submission of GraftAssureDx by year-end 2025 with an anticipated mid-2026 product launch. Key operational items include 11 clinical trial sites, a planned 5,000-participant registry collecting ~50,000 samples, finalized kitted product design, and Bio-Rad supply of instrumentation and certain reagents.
Financially, Q3 revenue was $260,000 from lab services and the company remains essentially pre-revenue for kitted sales. CMS reimbursement for the assay was set at $2,753 per result.